| Title |
Augmentation with antidepressants in schizophrenia treatment: benefit or risk
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, March 2015
|
| DOI | 10.2147/ndt.s62266 |
| Pubmed ID | |
| Authors |
Ye-Meng Mao, Ming-Dao Zhang |
| Abstract |
We focused on the application of antidepressants in schizophrenia treatment in this review. Augmentation of antidepressants with antipsychotics is a common clinical practice to treat resistant symptoms in schizophrenia, including depressive symptoms, negative symptoms, comorbid obsessive-compulsive symptoms, and other psychotic manifestations. However, recent systematic review of the clinical effects of antidepressants is lacking. In this review, we have selected and summarized current literature on the use of antidepressants in patients with schizophrenia; the patterns of use and effectiveness, as well as risks and drug-drug interactions of this clinical practice are discussed in detail, with particular emphasis on the treatment of depressive symptoms in schizophrenia. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 133 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Unknown | 132 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 26 | 20% |
| Student > Master | 14 | 11% |
| Researcher | 13 | 10% |
| Student > Doctoral Student | 12 | 9% |
| Student > Ph. D. Student | 11 | 8% |
| Other | 20 | 15% |
| Unknown | 37 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 40 | 30% |
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 12% |
| Psychology | 10 | 8% |
| Agricultural and Biological Sciences | 5 | 4% |
| Neuroscience | 5 | 4% |
| Other | 12 | 9% |
| Unknown | 45 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 April 2023.
All research outputs
#2,450,310
of 25,374,647 outputs
Outputs from Neuropsychiatric Disease and Treatment
#314
of 3,132 outputs
Outputs of similar age
#29,919
of 270,992 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#13
of 69 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 270,992 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.